Amylyx Pharmaceuticals Q2 Earnings Call Highlights

Key Points

• LUCIDITY trial results are expected in late August or early September. Amylyx has completed final patient visits in the Phase III avexitide study for post-bariatric hypoglycemia, with database cleaning and locking still underway.
• Amylyx is preparing for a potential U.S. avexitide launch in 2027, contingent on positive data and FDA approval. The company is building commercial capabilities and estimates roughly 160,000 U.S. patients have PBH after common bariatric procedures.
• The company ended Q2 with $250.8 million in cash and marketable securities, which management expects to fund operations into 2028. Amylyx also reported $45.7 million in quarterly operating expenses and continued advancing programs for Wolfram syndrome, ALS and other rare diseases.

Amylyx Pharmaceuticals NASDAQ: AMLX said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September.

The company remains blinded to the data and said the trial database has not yet been locked. LUCIDITY is a randomized, double-blind, placebo-controlled study evaluating 90 mg of avexitide once daily in adults with PBH following Roux-en-Y gastric bypass surgery.

Avexitide is an investigational GLP-1 receptor antagonist that has received FDA breakthrough therapy designation for PBH. The primary endpoint in LUCIDITY is the reduction in the composite of Level 2 and Level 3 hypoglycemic events through week 16, an outcome Amylyx said was agreed upon with the FDA.

Trial Readout and Regulatory Preparation

Chief Medical Officer Camille Bedrosian said the company is completing data-cleaning work and ensuring trial records are complete before locking the database. She said Amylyx has been “very diligent” because the database will be locked once for the 16-week double-blind core study.

Bedrosian said the Phase III population was designed to be consistent with patients enrolled in prior Phase II studies of avexitide. The company also said it monitored treatment compliance throughout the study, supported by site selection, a run-in period and ongoing oversight of participating clinical sites.

Co-CEO Josh Cohen said Amylyx believes the LUCIDITY 16-week double-blind results represent the final major component needed for its new drug application, or NDA. The company is preparing applicable NDA sections ahead of a potential submission, though management did not provide a filing timeline.

Management said the FDA could potentially limit an initial indication to PBH following Roux-en-Y gastric bypass because LUCIDITY enrolled only those patients. However, Co-CEO Justin Klee said the company intends to argue that PBH should be treated similarly regardless of the surgery that led to the condition, citing what it described as a shared underlying mechanism involving an exaggerated GLP-1 response.

Klee noted that the prior Phase IIb study allowed patients with different surgeries leading to PBH and that avexitide appeared to work across those groups. If the initial label is narrower, Amylyx believes additional evidence to support broader use could potentially be generated efficiently, although it did not provide a specific study design or timeline.

Commercial Planning Targets Potential 2027 Launch

Amylyx is preparing for a potential U.S. launch of avexitide in 2027, contingent on positive data and regulatory approval. The company has deployed a field medical affairs team and continued adding personnel in marketing, market access and commercial operations.

Chief Commercial Officer Dan Monahan estimated that about 160,000 people in the U.S. are living with PBH following the two most common bariatric procedures, Roux-en-Y gastric bypass and sleeve gastrectomy. He said the estimate is supported by claims analyses, field insights and published literature. Of that total, Klee said approximately 120,000 patients had Roux-en-Y gastric bypass associated with their PBH, based on Stanford prevalence work cited by the company.

Monahan said Amylyx has identified care settings with 50 to 60 PBH patients and, in some instances, up to 100 patients. The company expects to focus initial launch efforts on those centers before expanding outreach more broadly within the endocrinology community.

The company also launched a disease-state education campaign, “Uncover the Mystery of Post-Bariatric Hypoglycemia,” including the uncoverpbh.com website for healthcare professionals and patients. Amylyx said it received strong engagement at the ENDO 2026 meeting and observed growing familiarity with PBH among endocrinologists.

In June, CMS and the CDC published 2027 ICD-10 code files that include a PBH-specific code, which will take effect for patient encounters beginning Oct. 1, 2026. Monahan said the code recognizes PBH within the broader medical community and may assist with tracking and diagnosis, although he said an ICD-10 code is not required for reimbursement or for identifying patients through claims data.

Second-Quarter Financial Results

Amylyx ended the second quarter with $250.8 million in cash and marketable securities, down from $279.8 million at the end of the first quarter. Chief Financial Officer Jim Frates said the company expects its cash position to fund operations into 2028, including the LUCIDITY readout, a potential FDA approval and a possible commercial launch in 2027.

• Total operating expenses were $45.7 million, up 7% from the same quarter of 2025.
• Research and development expense was $23.8 million, compared with $27.2 million a year earlier.
• Selling, general and administrative expense was $21.9 million, compared with $15.6 million a year earlier.
• Non-cash stock-based compensation expense totaled $8.3 million, compared with $7.4 million in the prior-year quarter.

Frates attributed the decline in research and development expense primarily to lower spending on AMX0035 for progressive supranuclear palsy, partly offset by higher avexitide development costs. The increase in selling, general and administrative expense reflected increased legal expenses, including a one-time legal charge, and investments in commercial initiatives.

Broader Pipeline Updates

Beyond avexitide, Amylyx said 96-week data from the Phase II open-label HELIOS trial of AMX0035 in Wolfram syndrome continued to show stabilization or improvement in measures of glycemic control and vision. The company said it is continuing to assess the most efficient design for a potential Phase III trial in the multifactorial rare disease.

For AMX0114 in amyotrophic lateral sclerosis, Amylyx said it is enrolling Cohort 3 in the Phase I multiple-ascending-dose LUMINA trial after what it characterized as a favorable safety profile to date.

The company also said IND-enabling studies are underway for AMX0318, a long-acting GLP-1 receptor antagonist, with an investigational new drug filing targeted for 2027. Amylyx entered a second research collaboration with peptide-specialist Gubra in July to identify candidates for another rare endocrine disease, but did not disclose the target indication.

About Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source